Thermo Fisher Scientific (TMO) Investor Day 2024 summary

Strategic Vision and Market Outlook

• Focus on enabling customer success through innovation, productivity, and trusted partnerships across life sciences, diagnostics, and applied markets.

• End markets estimated at $235 billion, with long-term growth projected at 4%-6%, driven by demographics, scientific advances, and increased demand for biologics and advanced therapies.

• Maintains industry leadership with $42.3B in revenue and over 120,000 employees, serving fast-growing end markets such as pharma, biotech, diagnostics, and advanced materials.

• Recovery from pandemic-related volatility is ongoing, with gradual improvement expected and a return to historical growth rates anticipated.

• China expected to return to approximately 10% long-term growth, aided by multi-year government stimulus, though timing remains uncertain.

Growth Strategy, Innovation, and Business Execution

• Proven growth strategy centers on high-impact innovation, trusted partner status, and an unparalleled commercial engine, driving consistent share gains.

• Organic growth target of 7%-9% in normal market conditions, outpacing 4%-6% underlying market growth, with share gains of 2-3% above market growth.

• Annual R&D investment of $1.3 billion supports leadership in proteomics, genomics, structural biology, and bioproduction, with 7,200 scientists and a robust innovation pipeline.

• Recent M&A, including PPD, The Binding Site, and Olink, have expanded capabilities in clinical research, diagnostics, and proteomics, with strong early performance and synergy realization.

• Commercial engine leverages digital platforms, on-site engagement, and global reach to deepen customer relationships and drive growth.

Capital Deployment and M&A

• Capital deployment prioritizes high-ROI investments, disciplined M&A (60–75% of capital), and shareholder returns through buybacks and dividends.

• Recent acquisitions: PPD (clinical research), The Binding Site (specialty diagnostics), and Olink (proteomics), each delivering strong financial and strategic synergies.

• Olink expected to deliver over $200M revenue in 2024 and mid-teens organic growth long-term.

• Share buybacks of $3B completed in Q1 2024; dividends increased 11% from 2023.

• M&A pipeline remains robust, with disciplined execution and integration expected to continue driving value.